Veru (VERU) Cost of Revenue (2012 - 2024)
Veru (VERU) posted quarterly Cost of Revenue of $2.9 million for Q4 2024, up 192.9% year-over-year from $990274.0 in Q1 2024, and down 26.93% quarter-over-quarter from $4.0 million in Q3 2024.
Veru (VERU) Cost of Revenue (2012 - 2024) Analysis & Trends
Veru (VERU) has reported Cost of Revenue for 13 consecutive years, with $2.9 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Cost of Revenue rose 192.9% year-over-year to $2.9 million; the TTM figure through Sep 2025 stood at $2.9 million (down 73.71% YoY), while the FY2025 annual figure was $2.9 million, down 73.71% from the prior year.
- Cost of Revenue fell to $2.9 million in Q4 2024 per VERU's latest filing, from $4.0 million in the prior quarter.
- Across five years, Cost of Revenue topped out at $4.0 million in Q3 2024 and bottomed at $990274.0 in Q4 2023.
- Historically, Cost of Revenue has averaged $2.7 million across 5 years, with a median of $2.5 million in 2020.
- Annual changes were most pronounced in 2020 — Cost of Revenue plunged 47.56% — and 2024, when it soared 192.9%.
- Veru's Cost of Revenue stood at $3.8 million in 2020, then sank by 39.34% to $2.3 million in 2021, then fell by 21.25% to $1.8 million in 2022, then tumbled by 45.16% to $990274.0 in 2023, then jumped by 192.9% to $2.9 million in 2024.
- Business Quant data shows VERU's Cost of Revenue at $2.9 million in Q4 2024, $4.0 million in Q3 2024, and $2.6 million in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 145.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 93.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 174.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 298.26 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 387.98 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 67.21 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Veru | 60.85 Mn | 35.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 2.90 Mn |
| Dec 31, 2024 | 2.90 Mn |
| Sep 30, 2024 | 3.97 Mn |
| Sep 30, 2024 | 3.97 Mn |
| Jun 30, 2024 | 2.62 Mn |
| Jun 30, 2024 | 2.62 Mn |
| Mar 31, 2024 | 3.46 Mn |
| Mar 31, 2024 | 3.46 Mn |
| Dec 31, 2023 | 990,274.00 |
| Dec 31, 2023 | 990,274.00 |
| Sep 30, 2023 | 2.32 Mn |
| Sep 30, 2023 | 2.32 Mn |
| Jun 30, 2023 | 2.11 Mn |
| Jun 30, 2023 | 2.11 Mn |
| Mar 31, 2023 | 2.49 Mn |
| Mar 31, 2023 | 2.49 Mn |
| Dec 31, 2022 | 1.81 Mn |
| Dec 31, 2022 | 1.81 Mn |
| Sep 30, 2022 | 2.08 Mn |
| Sep 30, 2022 | 2.08 Mn |